278 results about "Neoplastic disease" patented technology

A method based on a multi-task learning model comprises the following steps: acquiring and processing histopathological image data of gastritis through a data preparation and preprocessing step; feature extraction is performed by using a self-supervised learning pre-trained model, and image blocks are coded into high-dimensional feature vectors; and constructing a multi-task learning model, learning feature representation through a full connection layer module and an attention layer module, and outputting a classification result of each task. And carrying out model training and optimization by using an optimizer, adding multitask loss through a loss function, and dynamically adjusting the model performance. The trained model can automatically detect and grade gastritis, atrophy, acute activity, intestinal metaplasia and other pathological indexes, outputs a standardized evaluation result, and assists in pathological diagnosis. According to the method, a multi-task deep learning framework based on self-supervised learning pre-training is constructed, a traditional single-task modeling mode is broken through, deep learning framework design is driven through pathological index association, and accuracy and clinical practicability of non-neoplastic disease assessment of the stomach are remarkably improved.

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The disclosure includes compounds of any one of Formulae (0)-(5), (11)-(24), (A)-(E), and (1)-(V) comprising an E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase, as described herein. Also disclosed pharmaceutical compositions comprising compounds, and a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The disclosure includes compounds of Formulae (1) wherein Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Qx, R1, R2, R3, R4, R5, R6, R7, R9, R10, R11, Rx, a, b, c, g, j, k, m, n, u, v, L, Z1, Z2, Z4, and Z5 are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

The disclosure includes compounds of Formula (A):wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, preferably a camptothecin cytotoxic molecule which is cell-permeable; and as a second payload a topoisomerase I inhibitor which is not cell-permeable, preferably a camptothecin cytotoxic molecule which is not cell-permeable. Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described is an ADC for use in a method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention discloses application of a Lys35 site of a PC4 protein as a target spot in preparation of tumor diagnosis and treatment products. The invention provides application of a Lys35 site of a PC4 protein as a target spot in preparation of a tumor diagnosis product. The research shows that the Lys35 site methylation of the PC4 protein can promote the cell cycle progress of tumor cells and promote the proliferation growth and malignant progression of the tumor cells, and the scheme for inhibiting the site methylation can be used for developing tumor treatment drugs. Therefore, the Lys35 site of the PC4 protein can be used as a key target to be applied to development of tumor diagnosis products and targeted therapy drugs. The invention further develops the PC4 protein Lys35 methylation antigen peptide and the antibody capable of specifically recognizing the PC4 protein Lys35 methylation site, and the PC4 protein Lys35 methylation antigen peptide and the antibody can be applied to regulation and control of tumor cell proliferation or growth, can be used for developing diagnostic products and targeted therapy drugs for clinical tumor diseases, and have good clinical application value.

The invention discloses a brain tumor disease treatment effect evaluation method, and belongs to the technical field of radiotherapy plan evaluation, and the method specifically comprises the steps: obtaining the brain multi-modal image data of a patient, and extracting a three-dimensional tumor region and a corresponding perfusion parameter; constructing a biological target region hierarchical structure containing a tumor overall region and an anoxic subregion; a relative hypoxia degree parameter is obtained by calculating the cerebral blood flow ratio of the hypoxia subregion to other regions of the tumor; historical treatment case data are deconstructed, and a dose-curative effect associated parameter set is established; training and outputting a dose adjustment strategy model for the hypoxia subregion; and generating a final radiotherapy dose planning scheme according to a dose adjustment value output by the model in combination with a clinical guide basic dose. Through a data-driven dose decision-making mechanism, the limitation of traditional uniform dose irradiation is overcome, so that an objective and reliable evaluation basis is provided for clinical selection and optimization of personalized treatment schemes.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, e.g., a camptothecin cytotoxic molecule which is cell-permeable; as a second payload a topoisomerase I inhibitor which is not cell-permeable, e..g., a camptothecin cytotoxic molecule which is not cell-permeable; and as a as a third payload a toxin or a cytotoxin, e.g., an auristatin such asMMAE (Monomethyl auristatin E). Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention relates to a multiple miRNA (micro Ribonucleic Acid) detection method based on deoxyribozyme or CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / The detection method provided by the invention comprises the following steps: designing a probe 1 and a probe 2 matched with different targets according to the different targets; when a target exists, the probe 1 and the probe 2 are connected to miRNA through T4DNA liguase, then DNA polymerase is introduced for amplification of a DNA chain, the released miRNA is further hybridized with a new probe, the next round of reaction is activated, and signals are circularly amplified. The S1 duplex body generated after amplification can be subjected to multiple characterization through two design modes: the first mode is based on deoxyribozyme detection; and the second mode is to carry out detection based on CRISPR / Cas12a. The method provided by the invention can realize detection of multiple tumor miRNAs, is short in detection time, and provides an important theoretical basis for treatment of tumor diseases.

The invention relates to the technical field of biological medicines, and particularly discloses a transcription factor HOMEZ phosphorylation site specific antibody as well as a preparation method and application thereof. The specific antibody provided by the invention can specifically recognize phosphorylation of the 451st site threonine of HOMEZ in a tumor specimen, so that the prognosis condition of the tumor is judged, and a potential action target is provided for clinical diagnosis and treatment of the tumor; moreover, the specific antibody disclosed by the invention can be used for detecting the expression difference between normal cells and tumor cells in a Western blot experiment, and is beneficial to research on the effect of phosphorylation modification of HOMEZ protein in the occurrence and development process of tumor diseases; and the kit can also be used for detecting the phosphorylation level of the HOMEZ protein in a clinical specimen through experiments such as immunofluorescence and immunohistochemical staining, and has a wide clinical application prospect in the aspects of disease diagnosis, treatment, prognosis judgment and the like.

The disclosure includes compounds of Formula (A):wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

The invention relates to the field of antibodies, and discloses an anti-canine PD-1 antibody and application thereof in prevention and treatment of mammal tumors, in particular to application in prevention and treatment of canine tumors. The high-affinity and high-activity canine PD-1 antibody can achieve the purpose of treating canine tumor diseases by blocking the binding of the canine PD-1 and the ligand of the canine PD-1.

The use of a combination of a pyrido[2,3-d]pyrimidin-2(1H)-one derivative and an anti-PD-1 or anti-PD-L1 antibody and / or a chemotherapeutic drug in the preparation of a drug for preventing or treating a tumor disease.

The invention relates to genetically modified arenaviruses suitable for the treatment of neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for treatment of neoplastic diseases and / or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus, wherein the arenavirus has been engineered to include a nucleotide sequence encoding one or more antigenic fragment(s) of mutant KRAS alone or to further include a nucleotide sequence encoding one or more antigenic fragment(s) of a mutated cancer driver gene (e.g., a mutant TP53) or a tumor-associated antigen.

The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The invention belongs to the field of natural medicines and medicinal chemistry, and discloses a thiotriptolide derivative and a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention discloses a thiotriptolide derivative shown as a general formula I and a general formula II. The derivatives are prepared in an artificial synthesis mode, pharmaceutical compositions containing the derivatives, and uses of the derivatives in preparation of drugs for treating tumor diseases.

In one aspect, the disclosure relates to immunogenic compositions comprising a semisynthetic saponin adjuvant (VSA) including, but not limited to, VSA-1 and VSA-2, derived from a Momordica saponin and at least one antigen. In a further aspect, the immunogenic compositions can include other known adjuvants, emulsifiers, and / or surface-active agents and can be formulated as liposomes, micelles, emulsions, and the like. Also disclosed are methods of eliciting effective immune responses to viral, bacterial, protozoal, and neoplastic diseases using the disclosed immunogenic compositions.

The invention relates to organic chemistry, pharmacology and medicine and concerns novel peptides characterized in that they exhibit antitumour activity, which can be used, in particular, for the prophylaxis and treatment of neoplastic diseases in a subject. In addition, the present invention also includes the use of the claimed peptides for the treatment of neoplastic diseases, as well as pharmaceutical compositions for the treatment of neoplastic diseases which contain the claimed peptides.

The invention belongs to the field of molecular fluorescent probes, and particularly discloses a near-infrared fluorescent probe of quinone oxidoreductase 1 (NAD (P) H: quinone oxidoreductase 1, NQO1) with an in-situ covalent anchoring function and a preparation method of the near-infrared fluorescent probe. According to the probe, dicyanoisophorone is used as a core fluorophore, an aldehyde group is used as an NQO1 covalent anchoring group, and 3-methyl-3-(2, 4, 5-trimethyl-3, 6-dioxocyclohex-1, 4-diene-1-yl) butyrate is used as a recognition group of NQO1. The invention also provides an application of the near-infrared fluorescent probe with the in-situ covalent anchoring NQO1. Compared with other probes, the probe is simple in synthesis method and suitable for industrial production, and has high sensitivity, high selectivity and good biocompatibility in NQO1 detection. The fluorescent probe disclosed by the invention can realize covalent labeling and in-situ imaging functions after target NQO1 recognition response. Long-time in-situ tracking and imaging can be carried out on tumor cells and tissues by monitoring the NQO1 level, and a simple and effective method is provided for accurate detection of tumor disease related protease.

Various embodiments of the invention provide binding agents for glypican-3 (GPC3), including antibodies or antigen-binding fragments thereof that bind to GPC3 and antigen recognizing receptors (e.g., CARs) that target GPC3 including cells that express GPC3. Embodiments of the i n vention also provide cells comprising such binding agents such as CAR T-cells, therapeutic compositions comprising such cells and methods of using one or more of the binding agents, cells or therapeutic compositions for the treatment of diseases or disorders associated with GPC3 expression such as various neoplastic diseases or disorders (e.g., hepatocellular carcinoma). Various embodiments of the invention also provide methods and systems for treati ng hepatocellular carcinoma (HCC) utilizing a combi nation of radiofrequency (RF) ablation and GPC3-targeted cell therapy. In certain embodiments, immune modulators, such as checkpoint inhibitors, may be co-administered to potentiate immune responses. Additionally, compositions and kits comprising RF ablation devices and GPC3-targeted cell therapy formulations are provided.

The present invention discloses biphenyloxadiazole ether derivatives as immune checkpoint inhibitors capable of blocking the PD-1 / PD-L1 signaling pathway, as well as their preparation methods and uses. These compounds, as shown in Formula I below, can modulate the PD-1 / PD-L1 signaling pathway to treat a variety of related tumor diseases through tumor immunotherapy, demonstrating potential drug development. The biphenyloxadiazole ether derivatives of the present invention, or their pharmaceutically acceptable salts, racemates, optical isomers, or solvates, are also disclosed. #imgabs0#

The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10, and wherein R1, X, R2 and R10 are as defined in the claims, as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.

The invention discloses an oligopeptide derivative based on lysosomal membrane protein 2A and application of the oligopeptide derivative. The oligopeptide derivatives disclosed by the invention are L2AK104, L2AK289, L2AK132 and L2ASIM1, and the amino acid sequences of the oligopeptide derivatives are shown as SEQ ID No.6 to SEQ ID No.9 in sequence. The oligopeptide derivative is composed of cell-penetrating peptides and oligopeptides, the oligopeptides are oligopeptides based on K104, K289, K132 and SIM1 sites modified by lysosomal membrane protein 2A polypeptide SUMO, and the amino acid sequences of the oligopeptides are sequentially shown as SEQ ID No.1-4; the cell-penetrating peptide is connected to the N terminal of the short peptide, and the amino acid sequence of the cell-penetrating peptide is shown as SEQ ID No.5. The four oligopeptide derivatives in the invention do not influence the cell activity and have no cytotoxicity, and the tumor virus KSHV is used as a research model, and in-vivo experiments repeatedly confirm that the four oligopeptide derivatives have a certain inhibition effect on the infection of viruses such as the KSHV and the proliferation of tumor cells. The compound can be used for preparing related drugs for resisting KSHV virus infection and treating tumor diseases, and has important application value in prevention and targeted treatment of virus related diseases such as KSHV.

The invention belongs to the technical field of biomedicine, and particularly relates to a polypeptide, an immunogen, a polyclonal antibody for detecting hnRNPK protein K163 site lactylation and a preparation method and application of the polyclonal antibody. The invention provides an hnRNPK protein K163 site lactylated polypeptide, the polypeptide is used for preparing an immunogen to further prepare a lactylated antibody aiming at the hnRNPK protein K163 site, the lactylated antibody can be used for tumor diagnosis, curative effect judgment or prognosis judgment products, and research on the application of the lactylated modification of the hnRNPK protein in tumor diseases, tumors, tumors and the like is facilitated. The invention has the effect of inhibiting glioma, especially in the occurrence and development process of children glioma, and provides a potential action target for diagnosis or treatment of clinical tumor diseases.